







FIG. 2B

FIG. 2A




FIG. 2C





FIG. 3B

FIG. 3A







FIG. 4A



**FIG. 4C**




FIG. 5B




FIG. 5A




FIG. 5C




FIG. 6




FIG. 7B




FIG. 7A




FIG. 7C




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 9B




FIG. 9A




FIG. 9C






FIG. 11B




FIG. 11A




FIG. 11C




FIG. 12B

FIG. 12A

Lipid Particle Formulation No. 79 (MC-3)  
Lipid Particle Formulation No. 80 (SS-OP)




FIG. 12C

Lipid Particle Formulation No. 79 (MC-3)  
Lipid Particle Formulation No. 80 (SS-OP)




FIG. 13

CD4+ T effector cells

MOG:I-A<sup>b+</sup> CD44<sup>hi</sup> FR4<sup>+</sup> CD73<sup>+</sup>






FIG. 14




Lipid Particle  
Formulation No. 14  
i.v

FIG. 15A




Lipid Particle  
Formulation No. 14  
i.p

FIG. 15B




Lipid Particle  
Formulation No. 1  
(frozen, 2w)

FIG. 15C



Lipid Particle  
Formulation No. 1  
i.v

FIG. 15D



Lipid Particle  
Formulation No. 1  
i.p

FIG. 15E




FIG. 16

Lipid Nanoparticle Formulation No. 1





FIG. 17A

FIG. 17B

FIG. 17C

**Therapeutic Treatment with LNP Encoding MOG Antigen mRNA Reverses Paralysis in a Mouse Model of MS\***




FIG. 18B

**Prophylactic Treatment with LNP Encoding MOG Antigen mRNA Prevents Paralysis in a Mouse Model of MS\***




FIG. 18A




FIG. 19B




FIG. 19A




FIG. 20A




FIG. 20B




FIG. 20C




FIG. 21




FIG. 22B




FIG. 22A




FIG. 23A




FIG. 23B




FIG. 24




FIG. 25A

FIG. 25B

FIG. 25C




FIG. 25D

FIG. 25E




FIG. 26




FIG. 27




FIG. 28B

FIG. 28A




FIG. 29




FIG. 30B

FIG. 30A




FIG. 30C




FIG. 30D




FIG. 31B




FIG. 31A




FIG. 31C




FIG. 32C




FIG. 32B




FIG. 32A




FIG. 32F




FIG. 32E





FIG. 32D




T=0 at 4°C

FIG. 33A




1 month at 4°C

FIG. 33B




Fresh

FIG. 33C



| Lipid Particle Formulation No. | 78      | 7       | 11      | 12      |
|--------------------------------|---------|---------|---------|---------|
| Chol/CHEMS Ratio               | 43.5/15 | 38.5/20 | 33.5/25 | 28.5/30 |
| Avg Spleen BLI                 | 8.17    | 9.9     | 5.03    | 4.16    |
| Avg Liver BLI                  | 11.33   | 4.35    | 0.78    | 0.59    |
| S/L ratio                      | 0.78    | 2.28    | 5.61    | 6.14    |

FIG. 34A



|                                |       |       |       |       |       |       |       |
|--------------------------------|-------|-------|-------|-------|-------|-------|-------|
| Lipid Particle Formulation No. | 77    | 75    | 76    | 7     | 8     | 9     | 10    |
| SSOP/CHEMS Ratio (X/Y)         | 55/5  | 50/10 | 45/15 | 40/20 | 35/25 | 30/30 | 25/35 |
| Avg Spleen BLI                 | 15.3  | 14.2  | 20.35 | 9.9   | 6.88  | 2.97  | 2.68  |
| Avg Liver BLI                  | 130   | 70.11 | 41.13 | 4.35  | 1.18  | 0.37  | 0.38  |
| S/L ratio                      | 0.117 | 0.202 | 0.495 | 2.28  | 5.83  | 8.02  | 7.05  |

FIG. 34B




FIG. 35B




FIG. 35A




FIG. 35C